Biochemical heterogeneity and developmental varieties in T-cell leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.Oncotarget · 2015
   Article
2. Single cell heterogeneity: why unstable genomes are incompatible with average profiles.Cell cycle (Georgetown, Tex.) · 2013
   Article
3. RasGRP Ras guanine nucleotide exchange factors in cancer.Frontiers in biology · 2013
   Article

Corrections and comments

• Comment on
  Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as